ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial
August 11, 2021ImmVira announced that it has initiated its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011). The first patient has been dosed, receiving MVR-T3011 intravenous (IV) administration in the U.S. on August 10, 2021. -
Keytruda combo set to become “standard of care” in kidney cancer
February 19, 2019Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a price advantage over BMS’ rival drug.....
Pharma Sources Insight January 2025
